Synonym
Nortilidine; 38677-94-0; 7145G6817J; (-)-nortilidine; UNII-7145G6817J
IUPAC/Chemical Name
ethyl (1R,6S)-6-(methylamino)-3,6-dihydro-[1,1'-biphenyl]-1(2H)-carboxylate
InChi Key
PDJZPNKVLDWEKI-GOEBONIOSA-N
InChi Code
InChI=1S/C16H21NO2/c1-3-19-15(18)16(13-9-5-4-6-10-13)12-8-7-11-14(16)17-2/h4-7,9-11,14,17H,3,8,12H2,1-2H3/t14-,16+/m0/s1
SMILES Code
CCOC([C@@]1(C2=CC=CC=C2)CCC=C[C@@H]1NC)=O
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
259.35
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Grün B, Merkel U, Riedel KD, Weiss J, Mikus G. Contribution of CYP2C19 and
CYP3A4 to the formation of the active nortilidine from the prodrug tilidine. Br
J Clin Pharmacol. 2012 Nov;74(5):854-63. doi: 10.1111/j.1365-2125.2012.04261.x.
PMID: 22381043; PMCID: PMC3495150.
2: Thierry C, Boeynaems JM, Paolo M. Actions of tilidine and nortilidine on
cloned opioid receptors. Eur J Pharmacol. 2005 Jan 4;506(3):205-8. doi:
10.1016/j.ejphar.2004.11.020. Epub 2004 Dec 15. PMID: 15627429.
3: Hajda JP, Jähnchen E, Oie S, Trenk D. Sequential first-pass metabolism of
nortilidine: the active metabolite of the synthetic opioid drug tilidine. J Clin
Pharmacol. 2002 Nov;42(11):1257-61. doi: 10.1177/009127002762491352. PMID:
12412825.
4: Weiss J, Sawa E, Riedel KD, Haefeli WE, Mikus G. In vitro metabolism of the
opioid tilidine and interaction of tilidine and nortilidine with CYP3A4,
CYP2C19, and CYP2D6. Naunyn Schmiedebergs Arch Pharmacol. 2008
Sep;378(3):275-82. doi: 10.1007/s00210-008-0294-7. Epub 2008 May 31. PMID:
18516595.
5: Eichbaum C, Mathes K, Burhenne J, Markert C, Blank A, Mikus G. Pre-systemic
elimination of tilidine: localization and consequences for the formation of the
active metabolite nortilidine. Basic Clin Pharmacol Toxicol. 2015
Feb;116(2):129-33. doi: 10.1111/bcpt.12328. Epub 2014 Oct 7. PMID: 25223231.